Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of Multiple Sclerosis: A Review
Stephen L. Hauser, Bruce Cree
The American Journal of Medicine (2020) Vol. 133, Iss. 12, pp. 1380-1390.e2
Open Access | Times Cited: 643

Showing 1-25 of 643 citing articles:

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
Pascal Benkert, Stéphanie Meier, Sabine Schaedelin, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 3, pp. 246-257
Open Access | Times Cited: 383
Neurotransmitters—Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System
Raluca Ioana Teleanu, Adelina-Gabriela Niculescu, Eugenia Roza, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 5954-5954
Open Access | Times Cited: 262
The Immune Response in Multiple Sclerosis
Sofía Rodríguez Murúa, Mauricio Farez, Francisco J. Quintana
Annual Review of Pathology Mechanisms of Disease (2021) Vol. 17, Iss. 1, pp. 121-139
Closed Access | Times Cited: 216
Locus for severity implicates CNS resilience in progression of multiple sclerosis
Adil Harroud, Pernilla Stridh, Jacob L. McCauley, et al.
Nature (2023) Vol. 619, Iss. 7969, pp. 323-331
Open Access | Times Cited: 123
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting
Marc Charabati, Michael A. Wheeler, Howard L. Weiner, et al.
Cell (2023) Vol. 186, Iss. 7, pp. 1309-1327
Open Access | Times Cited: 119
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
Christian Barro, Brian C. Healy, Yanqing Liu, et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 106
N6-methyladenosine and Neurological Diseases
Nan Zhang, Chunhong Ding, Yuxin Zuo, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 3, pp. 1925-1937
Closed Access | Times Cited: 102
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
Emily Kamma, Wendy O Lasisi, Cole D. Libner, et al.
Journal of Neuroinflammation (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 94
Ocrelizumab: A Review in Multiple Sclerosis
Yvette N. Lamb
Drugs (2022) Vol. 82, Iss. 3, pp. 323-334
Open Access | Times Cited: 86
Advances in Neurodegenerative Diseases
Jeroen Van Schependom, Miguel D’haeseleer
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1709-1709
Open Access | Times Cited: 80
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
Rongzeng Liu, Shushu Du, Lili Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 79
Regulatory Mechanism of M1/M2 Macrophage Polarization in the Development of Autoimmune Diseases
Yuan Peng, Mengxian Zhou, Yang Hong, et al.
Mediators of Inflammation (2023) Vol. 2023, pp. 1-20
Open Access | Times Cited: 66
Brain macrophage development, diversity and dysregulation in health and disease
Aymeric Silvin, Jiawen Qian, Florent Ginhoux
Cellular and Molecular Immunology (2023) Vol. 20, Iss. 11, pp. 1277-1289
Open Access | Times Cited: 61
Role of microbiota short-chain fatty acids in the pathogenesis of autoimmune diseases
Ashkan Rasouli‐Saravani, Kasra Jahankhani, Shadi Moradi, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114620-114620
Open Access | Times Cited: 48
Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview
Eman E. Alshial, Muhammad Idris Abdulghaney, Al-Hassan Soliman Wadan, et al.
Life Sciences (2023) Vol. 334, pp. 122257-122257
Closed Access | Times Cited: 48
Multifunctional Nanotheranostics for Overcoming the Blood–Brain Barrier
M H Miran Beygi, Fatemeh Oroojalian, Soheil Azizi‐Arani, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 19
Closed Access | Times Cited: 22
Border-associated macrophages in the central nervous system
Rui Sun, Haowu Jiang
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 20
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Marien González‐Lorenzo, Ben Ridley, Silvia Minozzi, et al.
Cochrane library (2024) Vol. 2024, Iss. 6
Open Access | Times Cited: 17
Alcohol Consumption and Autoimmune Diseases
Sergio Terracina, Brunella Caronti, Marco Lucarelli, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 845-845
Open Access | Times Cited: 2
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
Reinhard Hohlfeld
Brain (1997) Vol. 120, Iss. 5, pp. 865-916
Open Access | Times Cited: 367
Hypoxia-Inducible Factor (HIF) in Ischemic Stroke and Neurodegenerative Disease
Еlena V. Mitroshina, Maria O. Savyuk, Evgeni Ponimaskin, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 82
The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
Martin L. Dalefield, Brittany Scouller, Rabia Bibi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 60
MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes
Saba Bakhshi, Saeedeh Shamsi
International Immunopharmacology (2022) Vol. 106, pp. 108595-108595
Closed Access | Times Cited: 53
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis
Xi Wu, Lu Wang, Lu Shen, et al.
EBioMedicine (2022) Vol. 81, pp. 104102-104102
Open Access | Times Cited: 53
Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform
Miguel Pinto, Vera Silva, Sandra Barreiro, et al.
Ageing Research Reviews (2022) Vol. 79, pp. 101658-101658
Closed Access | Times Cited: 52
Page 1 - Next Page

Scroll to top